Separation, characterization, and standardization of extracellular vesicles for drug delivery applications

Extracellular vesicles (EVs) are membranous nanovesicles secreted from living cells, shuttling macromolecules in intercellular communication and potentially possessing intrinsic therapeutic activity. Due to their stability, low immunogenicity, and inherent interaction with recipient cells, EVs also hold great promise as drug delivery vehicles. Indeed, they have been used to deliver nucleic acids, proteins, and small molecules in preclinical investigations. Furthermore, EV-based drugs have entered early clinical trials for cancer or neurodegenerative diseases. Despite their appeal as delivery vectors, however, EV-based drug delivery progress has been hampered by heterogeneity of sample types and methods as well as a persistent lack of standardization, validation, and comprehensive reporting. This review highlights specific requirements for EVs in drug delivery and describes the most pertinent approaches for separation and characterization. Despite residual uncertainties related to pharmacodynamics, pharmacokinetics, and potential off-target effects, clinical-grade, high-potency EV drugs might be achievable through GMPcompliant workflows in a highly standardized environment. (c) 2021 Elsevier B.V. All rights reserved.

Automated summary

EVs are membrane nanovesicles secreted from living cells which have potential therapeutic activity and are being explored as drug delivery vehicles in preclinical investigations and early clinical trials. However, progress in EV-based drug delivery is hindered by heterogeneity of sample types and methods, as well as a persistent lack of standardization, validation, and comprehensive reporting.